 |
|
Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ.
A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med.
1997 Apr 24;336(17):1216-22.
PubMed Abstract
|
|
|
|
|
|
|
Comments on Related News |
|
|
| |
Related News: Antioxidants No Help for Alzheimer’s, Biomarker Trial Says
Comment by: Sanjay W. Pimplikar
|
|
|
Submitted 25 March 2012
| Permalink
|
Posted 25 March 2012
|
|
|
These conclusions are based on a four-month treatment, whereas most trials go on for 18 months, and some even for 36 months. Knowing the complexity of AD pathogenesis, would a four-month treatment be considered sufficiently long to test the efficacy of an approach?  View all comments by Sanjay W. Pimplikar |
|
|
| |
Related News: Antioxidants No Help for Alzheimer’s, Biomarker Trial Says
Comment by: Elena Galea
|
|
|
Submitted 26 March 2012
| Permalink
|
Posted 27 March 2012
|
|
|
I believe that the 19 percent decrease in isoprostane, however small, is very relevant because this is the first time that any antioxidant treatment in AD has been proven to engage its target. However, if oxidative stress is a culprit in AD, then antioxidant treatments, like any other disease-modifying drugs, should be tested at presymptomatic stages of the disease. View all comments by Elena Galea |
|
|
| |
Submit a Comment on this Paper |
|
|
|
|
| |
 |
|
| |
|
|
|
|
Home
